Off-Label Promotion Not Enough For Fed Intervention – Patton Boggs Lawyer
This article was originally published in The Pink Sheet Daily
Executive Summary
Justice Department is unlikely to investigate off-label drug claims unless a firm is also offering kickbacks or bilking Medicare or Medicaid, Laura Laemmle asserts, discussing recent case against drug firm Serono.